JS107 plus toripalimab and chemotherapy as first-line treatment for CLDN18.2-positive gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, open-label Phase 3 study comparing two first-line regimens for adults with unresectable locally advanced, recurrent, or metastatic CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma who have not received prior systemic therapy. Participants are assigned to JS107 plus toripalimab with oxaliplatin and capecitabine, or to sintilimab with oxaliplatin and capecitabine, as their XELOX backbone. The trial collects blinded progression-free survival and overall survival as dual primary endpoints, along with safety data. Eligible patients must have measurable disease, good performance status, and CLDN18.2 positivity confirmed centrally.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. The patient voluntarily participated, provided informed consent, signed a written informed consent form, and had good compliance.
2. Age ≥18 years (including), male and female. 3)Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4）Expected survival period ≥3 months.

5）Patients with HER2-negative, unresectable locally advanced, recurrent, or Metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma confirmed by histology/cytology. 6）Previously untreated for systemic therapy for locally advanced, recurrent, or Metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. 7）Positive for CLDN18.2 by IHC testing at the central laboratory. 8）According to the RECIST v1.1 criteria, the patient has ≥1 measurable lesion. 9）The functional level of the organ meets the requirements of the protocol. 10）Agree to use contraception during the study period; females of reproductive potential will undergo a blood pregnancy test within 7 days prior to randomization, with a negative result.

Exclusion Criteria:

1. Previously received any drug or cell therapy targeting CLDN18.2
2. Received major surgery, live vaccine administration, or Drug therapy with other investigational medicinal products, or received radiotherapy within 2 weeks prior to randomization.
3. Imaging shows cerebral tumor lesions (unless whole-brain radiotherapy or surgery, etc., local treatment has been completed, and imaging and clinical stability have been assessed according to the protocol) 4)Peripheral neuropathy ≥ Grade 2

5）Idiopathic pulmonary fibrosis, Organising pneumonia, drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia on screening chest computerised tomography (CT) scan 6）Pericardial effusion, Pleural effusion, or ascites with a large volume, or with clinical symptoms, or requiring symptomatic treatment.

7）There is a need for systemic antimicrobial or antiviral therapy for active infection.

8）Subjects who cannot take oral medications, require enteral nutrition to maintain feeding, or have Malabsorption syndrome or other conditions affecting gastrointestinal Malabsorption.

9）Presence of biliary or gastrointestinal obstruction, or persistent recurrent vomiting 10）Weight loss of \>10% within the previous 2 months or severe Malnutrition, known prior to randomization.

11）History of gastrointestinal perforation and/or fistula within the prior 6 months; presence of high-risk Haemorrhage of digestive tract disease or risk of rupture bleeding or gastrointestinal/respiratory fistula 12）Serious cardiovascular and cerebrovascular diseases 13）History of systemic treatment for autoimmune diseases within the past 2 years 14）Randomly selected patients with any other Neoplasm malignant within the past 5 years.

15）Known severe allergic reaction to any ingredient in the study drug formulation 16）Known active Hepatitis B, active Hepatitis C, human immunodeficiency (HIV) infection, or have undergone allogeneic stem cell or Solid organ transplant.

17）Diseases determined by researchers to be unsuitable for participation.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Bifeng Liu
• Email: bifeng_liu@junshipharma.com
• Phone: 021-61058800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sintilimab added to SOX chemotherapy after surgery for PD-L1–positive pN3 gastric cancer

  This trial will test whether adding the PD-1 blocker sintilimab to standard SOX chemotherapy after surgery helps people with PD-L1–positive, pathologic N3 gastric cancer stay cancer-free longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07263386

• Combining Sintilimab with Chemotherapy for Stage III Gastric Cancer Treatment

  This study is testing if combining a new drug called Sintilimab with chemotherapy can help people with stage III gastric cancer feel better after their surgery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06761846

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Propranolol with Toripalimab and Platinum Chemo before/around surgery in NSCLC

  This study tests whether adding propranolol to toripalimab and platinum-based chemotherapy is safe and tolerable for people with resectable non-small cell lung cancer before surgery.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886229

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.